Paul E Monahan is a prominent inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of gene therapy, holding a total of 3 patents. His work focuses on enhancing the delivery and efficacy of viral vectors for therapeutic applications.

Latest Patents

Monahan's latest patents include innovative methods and compositions for enhanced parvovirus transduction. One of his notable inventions provides methods for enhanced transduction of an adeno-associated virus (AAV) vector, which comprises a heterologous nucleic acid of interest. This invention employs a proteasome inhibitor to achieve an oversized AAV vector genome relative to a wild type AAV genome. Another significant patent involves methods and compounds for the controlled release of recombinant parvovirus vectors. This invention utilizes recombinant adeno-associated viruses (rAAV) to deliver genes and DNA sequences for gene therapy, particularly through the manipulation of the therapeutic virus for packaging and transport.

Career Highlights

Monahan is affiliated with the University of North Carolina at Chapel Hill, where he continues to advance research in gene therapy. His work has been instrumental in developing new strategies for viral vector delivery, which are crucial for effective gene therapy treatments.

Collaborations

Throughout his career, Monahan has collaborated with esteemed colleagues such as Richard Jude Samulski and Joseph E Rabinowitz. These collaborations have further enriched his research and contributed to the advancement of gene therapy technologies.

Conclusion

Paul E Monahan is a key figure in the field of gene therapy, with a focus on enhancing viral vector delivery systems. His innovative patents and collaborations reflect his commitment to advancing medical science and improving therapeutic outcomes.

This text is generated by artificial intelligence and may not be accurate.